RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Real-world incidence and management of adverse events (AEs) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide
Jiang, SC., Varghese, D., Appukkuttan, S., Corman, S., Kebede, N., Gnanasakthy, A., Macahilig, C., Waldeck, R., & Hassain, A. (2020). Real-world incidence and management of adverse events (AEs) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Journal of managed care & specialty pharmacy, 26(10-a Suppl), Article S89.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
